Drug intelligence / Profile preview

ASN512

Development stage: Unknown
Lead developer: Jiangsu Aosaikang Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

ASN512 is an orally bioavailable small molecule inhibitor of the Tropomyosin receptor kinase (TRK) family, including TRKA, TRKB, and TRKC. Developed by Jiangsu Aosaikang Pharmaceutical, it is currently in Phase 1 clinical development for the treatment of advanced solid tumors, with a particular focus on salivary gland tumors. The drug is designed to target oncogenic drivers such as NTRK gene fusions, which are prevalent in specific subtypes of salivary gland cancer like secretory carcinoma. By inhibiting the constitutive kinase activity of these fusion proteins, ASN512 aims to block downstream signaling pathways that promote tumor cell proliferation and survival.

Targets

NTRK1 (Tropomyosin-related receptor kinase A)NTRK3 (Tropomyosin receptor kinase C)NTRK2 (Tropomyosin-related kinase receptor type B)

Beyond the preview

Go deeper on ASN512.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ASN512.

Explore the full profile